Eli Lilly joins a troika of Big Pharmas that have tied up to a low-profile biotech with big aspirations in autoimmune disease, cancer
Eli Lilly has followed 3 major league pharma players down the deal path to ImmuNext, a biotech you may not know a whole lot about.
The low-profile biotech has reserved one segment of the R&D mission for immunometabolism, studying how you could regulate the immune system so that it would stop attacking healthy tissue, offering a new approach to autoimmune diseases. Their preclinical program focuses on regulating immune cell metabolism. And that’s where Lilly is stepping on board, joining the program with an aim to advance into human studies.
Basic subscription required
Unlock this story instantly and join 53,100+ biopharma pros reading Endpoints daily — and it's free.